搜尋結果
About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name: lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
Eisai is distributing the product in China and conducting information provision activities through specialized Medical Representatives, while also working to build a unique early AD diagnosis and treatment pathway that combines online and offline services.
About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s ...
Eisai Announces Appointments of Directors and Corporate Officers. Eisai Co., Ltd. announced that the following Directors and Corporate Officers for FY2024 were appointed by resolutions at the 112th Ordinary General Meeting of Shareholders and subsequent Board of Directors meeting held today. Directors (*Outside Directors) Board of Directors.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the European Medicines Agency (EMA), did not take place due to procedural reasons at the EMA.
About Brepacise. Brepacise is a dual-task exercise program that stimulates the body and brain by moving the arms and legs to music while also incorporating intellectual challenges. Eisai developed this product with the review of a physician as an easy and fun introductory exercise for those concerned about their brain health.
